AtriCure Inc. (ATRC) Shares Sold by Emerald Advisers Inc. PA

Emerald Advisers Inc. PA trimmed its position in shares of AtriCure Inc. (NASDAQ:ATRC) by 1.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 553,411 shares of the medical device company’s stock after selling 7,290 shares during the period. Emerald Advisers Inc. PA’s holdings in AtriCure were worth $10,094,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new position in AtriCure during the 3rd quarter valued at about $771,000. State Street Corp boosted its holdings in AtriCure by 4.0% during the 2nd quarter. State Street Corp now owns 617,405 shares of the medical device company’s stock valued at $14,971,000 after acquiring an additional 23,790 shares during the period. Skylands Capital LLC purchased a new position in AtriCure during the 4th quarter valued at about $1,368,000. UBS Asset Management Americas Inc. purchased a new position in AtriCure during the 2nd quarter valued at about $315,000. Finally, Vanguard Group Inc. boosted its holdings in AtriCure by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock valued at $35,083,000 after acquiring an additional 52,761 shares during the period. Institutional investors own 86.41% of the company’s stock.

AtriCure Inc. (NASDAQ ATRC) opened at $15.81 on Thursday. The company has a current ratio of 2.28, a quick ratio of 1.65 and a debt-to-equity ratio of 0.20. AtriCure Inc. has a 52 week low of $15.06 and a 52 week high of $25.18.

A number of brokerages recently commented on ATRC. Piper Jaffray Companies restated a “buy” rating and set a $24.00 target price on shares of AtriCure in a report on Sunday, December 10th. Needham & Company LLC lowered their target price on AtriCure from $26.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, November 2nd. ValuEngine cut AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. TheStreet cut AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. Finally, Canaccord Genuity decreased their price objective on AtriCure from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $24.33.

In other news, CFO M. Andrew Wade sold 2,000 shares of AtriCure stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $18.41, for a total value of $36,820.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/02/08/atricure-inc-atrc-shares-sold-by-emerald-advisers-inc-pa.html.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit